{"Clinical Trial ID": "NCT00201773", "Intervention": ["INTERVENTION 1:", "Exemestane + celecoxib", "Exemestane + celecoxib (16 weeks) compared to baseline", "INTERVENTION 2:", "- Exemestane", "\u2022 Exemestane (8 weeks) compared to the reference level"], "Eligibility": ["Incorporation criteria:", "Must be a woman with breast cancer confirmed by histology", "Phase II-IV of the disease", "RA and/or PR positive", "ECOG Performance Status 0-1", "The tumours should be present following the needle biopsy, determined by physical examination or radiographic evaluation.", "Postmenopausal menopausal", "No other active cancer is allowed.Basal cells, squamous skin cancer, cervical cancer in situ or any other cancer whose patient has been free for 5 years are allowed.Biphosphonates and palliative radiation for bone metastasis are allowed during the study.", "The hormone replacement therapy should be discontinued. It is not allowed during the duration of the study.", "- Exclusion criteria:", "A known history of asthma, urticaria or allergic reactions induced by aspirin or NSAID; or an allergy to sulphonamides severe enough in nature to require emergency room treatment or hospitalization.", "History of myocardial infarction or other thrombotic events.", "Inflammatory breast cancer (edema or ulceration of the breast skin).", "Significant renal dysfunction (serum creatinine > 1.5 x upper limit of normal).", "Significant hepatic dysfunction (serum bilirubin > 1.5 x upper limit of normal or AST, ALT > 3 x upper limit of normal)", "ANC < 1.5, platelets < 100,000 K/uL and hemoglobin < 9 g/dL.", "The use of other COX-2 inhibitors such as rofecoxib (Vioxx\u00ae, aspirin, trisalicylate (Trilisate\u00ae)) is not permitted during the duration of the study.", "The use of NSAID such as ibuprofen (Advil\u00ae or Motrin\u00ae), naproxyn (Aleve\u00ae Naprosyn\u00ae or Anaprox\u00ae), etodolac (Lodine\u00ae), oxaproxine (Daypro\u00ae), difusanil (Dolobid\u00ae), nabumetone (Relafin\u00ae) or tolmetin (Tollotin\u00ae) is not permitted during the duration of the study."], "Results": ["Performance measures:", "Number of patients with decreased gene expression of CYP19 in breast cancer by adding a COX-2 inhibitor to exemestane", "Collection of postmenopausal women receiving exemestane neoadjuvant.", "Time limit: up to 16 weeks", "Results 1:", "Title of the arm/group: Exemestane + Celecoxib", "Description of the arm/group: Exemestane + celecoxib (16 weeks) relative to the reference base", "Total number of participants analysed: 14", "Type of measurement: Number", "Unit of measure: patients 0", "Results 2:", "Title of the arm/group: Exemestane", "Description of the arm/group: Exemestane (8 weeks) relative to the reference base", "Total number of participants analysed: 9", "Type of measurement: Number", "Unit of measure: patients 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 0/22 (0.00 per cent)", "Adverse Events 2:", "Grand total"]}